The Generic and Biosimilar Medicines Association (GBMA) is pleased to announce the appointment of Nikki Lorenz as its new Chief Executive Officer.
Commencing April 13, Ms Lorenz brings extensive experience in the pharmaceutical and healthcare sector, with a strong track record of strategic leadership, stakeholder engagement, and advancing patient access to medicines. Her appointment comes at a critical time as GBMA continues to champion sustainable access to medicines for Australian patients.
GBMA Chair, Hon Prof. Jane Halton AO PSM welcomed the appointment, noting Ms Lorenz’s deep industry expertise and leadership capability.
“Nikki is an outstanding leader with a clear vision for the future of generic and biosimilar medicines in Australia. Her experience and commitment to improving patient access and system sustainability make her exceptionally well placed to lead GBMA into its next phase,” Jane said.
Jane also acknowledged the significant contribution of outgoing CEO, Marnie Peterson. “On behalf of the Board and our members, I would like to sincerely thank Marnie for her unwavering commitment to GBMA and her leadership during a period of considerable change and challenge. Marnie has played a critical role in strengthening the organisation and advancing the interests of our members.”
“We are particularly grateful for Marnie’s dedication to ensuring a smooth and seamless transition, and for her continued support of GBMA and its members.”
Ms Lorenz said she was honoured to take on the role and lead the organisation at such an important time. “I am delighted to be joining GBMA and working alongside its members and stakeholders to ensure Australians continue to have timely and affordable access to essential medicines,” Ms Lorenz said.
“There is a significant opportunity to strengthen the role of generic and biosimilar medicines in delivering a more sustainable and resilient healthcare system, and I look forward to building on the strong foundation established by Marnie and the team.”
Nikki brings senior leadership experience from association exposure across policy, advocacy and member engagement, with a strong focus on medicines access, pricing and regulatory reform. Her ability to navigate complex policy environments and work closely with government and industry positions her well to advance GBMA’s priorities and support sustainable access to medicines.
Nikki will address GBMA’s post-budget luncheon, where she looks forward to meeting with members, stakeholders and industry colleagues, and engaging in discussions on the policy and funding settings shaping the future of medicines access in Australia.
GBMA remains committed to working collaboratively with government, industry, healthcare professionals and patient groups to address medicine shortages and improve equitable access to treatments across Australia.
Generic and Biosimilar Medicines Association
Level 17, 1 Denison St, North Sydney, NSW 2060
admin@gbma.com.au
ABOUT GBMA
The Generic and Biosimilar Medicines Association (GBMA) is the peak representative body of generic and biosimilar medicine suppliers in Australia. Its members ensure that all Australians are offered the highest quality generic and biosimilar medicines in the world whilst providing affordable community health outcomes that benefit all Australians.
